Compare OLB & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLB | MYNZ |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.8M |
| IPO Year | N/A | 2021 |
| Metric | OLB | MYNZ |
|---|---|---|
| Price | $0.90 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 46.1K | ★ 188.9K |
| Earning Date | 11-14-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,639,651.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.92 |
| 52 Week High | $2.50 | $8.20 |
| Indicator | OLB | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 54.02 |
| Support Level | $0.90 | $1.00 |
| Resistance Level | $1.02 | $1.15 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 3.89 | 76.27 |
The OLB Group Inc is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise. It focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. Along with its subsidiaries, the company offers a cloud-based business management platform that provides turnkey solutions for merchants to enable them to build and manage their retail businesses, whether online or at a brick-and-mortar location, payment processing solutions, payment gateway, virtual terminal with proprietary business management tools, and crowdfunding solutions. The company has two business segments; Fintech Services which generates key revenue, and the Bitcoin Mining business segment.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.